Mycophenolic Acid

證據等級: L5

預測適應症: 10 個

Mycophenolic Acid: From Organ Transplant Rejection Prevention to Hemoglobinopathy

One-Sentence Summary

Mycophenolic acid (MPA) is the active metabolite of mycophenolate mofetil (MMF), an established immunosuppressant used globally to prevent rejection in solid organ transplant recipients and to treat autoimmune conditions such as lupus nephritis — though it currently has no Philippines regulatory registration. The TxGNN model predicts it may be effective for Hemoglobinopathy (encompassing sickle cell disease and thalassemia major), with 27 clinical trials and 9 publications supporting its role as GVHD prophylaxis enabling curative hematopoietic stem cell transplantation for these conditions.

Quick Overview

Item	Content
Original Indication	Organ transplant rejection prevention (renal, cardiac, hepatic allografts) and lupus nephritis — not registered in Philippines
Predicted New Indication	Hemoglobinopathy (sickle cell disease, thalassemia major)
TxGNN Prediction Score	99.60%
Evidence Level	L2
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Mycophenolic acid (MPA) is the active metabolite of mycophenolate mofetil (MMF). Formal mechanism of action data is not available from the Philippines regulatory record; however, based on published evidence, MPA acts as a selective, non-competitive inhibitor of inosine monophosphate dehydrogenase (IMPDH) — specifically the type II isoform (IMPDH2) predominantly expressed in activated lymphocytes. Because T and B lymphocytes rely almost entirely on the de novo purine synthesis pathway for proliferation (rather than salvage pathways), IMPDH inhibition selectively suppresses lymphocyte expansion without substantially affecting other cell types. This mechanism was characterised in foundational in vitro work as early as 1991 (PMID 1826793) and underpins MPA’s established role in all transplant immunosuppression settings.

In the context of hemoglobinopathy, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative therapy for sickle cell disease and thalassemia major. The critical barriers to cure are graft-versus-host disease (GVHD) and graft rejection. MMF is used as a core component of GVHD prophylaxis regimens: by selectively suppressing donor and recipient lymphocyte proliferation, it stabilises mixed chimerism — the coexistence of donor and host hematopoietic cells — which ultimately allows functional replacement of the defective erythropoiesis. A 2023 publication directly reports “Immunosuppression Boost with MMF for Mixed Chimerism in Thalassemia Transplants” (Transplantation and Cellular Therapy, PMID 36372358), providing direct mechanistic and clinical confirmation of this link.

The connection between MPA’s established transplant immunosuppression role and hemoglobinopathy HSCT is therefore mechanistically coherent and clinically intuitive: the same lymphocyte-suppressive mechanism that prevents solid organ rejection is equally applicable to preventing GVHD following HSCT for hemoglobinopathy. Active clinical adoption is confirmed by a 2025 population pharmacokinetic dosing guideline specifically addressing MMF in pediatric thalassemia patients undergoing HSCT (PMID 39891881).

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04009525	Phase 4	Completed	823	Multicenter prospective study of allo-HSCT efficacy in thalassemia major; MMF is a core GVHD prophylaxis component in the standard regimen
NCT02342145	Phase 4	Completed	205	Multicenter RCT evaluating basiliximab for acute GVHD prevention in unrelated allo-HSCT for thalassemia major; MMF used as core background immunosuppression
NCT03263559	Phase 2	Completed	95	Phase II multicenter trial of haploidentical BMT for symptomatic sickle cell disease; assessed engraftment and toxicity in paediatric and adult patients
NCT00919503	Phase 2	Completed	98	Treosulfan + fludarabine preparative regimen for nonmalignant disorders including hemoglobinopathies; MMF incorporated as post-transplant immunosuppression
NCT01050855	Phase 2	Active, not recruiting	75	Phase II RIC pilot study for non-malignant diseases including hemoglobinopathies; bone marrow or cord blood as stem cell source
NCT06872333	Phase 2	Recruiting	62	Open-label Phase II trial of allo-HSCT for high-risk hemoglobinopathies and red cell transfusion-dependent disorders; currently enrolling
NCT03121001	Phase 2	Recruiting	50	HLA-haploidentical HSCT with low-dose TBI for clinically aggressive sickle cell disease; MMF included in GVHD prophylaxis protocol
NCT02867800	Phase 1	Completed	24	Abatacept added to standard GVHD prophylaxis (calcineurin inhibitor + methotrexate) after HSCT for paediatric sickle cell disease; MMF used as comparator background therapy
NCT04644016	Phase 2	Recruiting	31	Cord blood transplantation for life-threatening non-malignant hematologic disorders without matched related donors; assessing 1-year treatment-related mortality
NCT01917708	Phase 1	Completed	10	Tolerability of abatacept combined with cyclosporine and mycophenolate mofetil as GVHD prophylaxis in children receiving unrelated donor HSCT for serious non-malignant diseases

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39891881	2025	Clinical Dosing Guideline	Eur J Drug Metab Pharmacokinet	Population PK model and dosing recommendations for MMF in paediatric thalassemia patients undergoing HSCT; fills a critical gap in off-label dosing
36372358	2023	Retrospective Cohort	Transplant Cell Ther	MMF immunosuppression boost for declining mixed chimerism in thalassemia transplants; directly demonstrates MMF’s role in sustaining donor engraftment
29061531	2018	Retrospective Cohort	Biol Blood Marrow Transplant	Unrelated donor HSCT for severe sickle cell disease with myeloablative busulfan/fludarabine/ATG regimen; tacrolimus and MMF used for GVHD prophylaxis
28578010	2017	Prospective Cohort	Biol Blood Marrow Transplant	Unrelated cord blood transplantation with RIC for sickle cell disease; addition of thiotepa improved engraftment rates
26860634	2016	Retrospective Cohort	Biol Blood Marrow Transplant	Alternative-donor HSCT with post-transplant cyclophosphamide for nonmalignant paediatric disorders including hemoglobinopathies and immunodeficiencies
18940682	2008	Prospective Cohort	Biol Blood Marrow Transplant	Stable long-term donor engraftment following RIC-HCT from HLA-matched sibling donors for high-risk sickle cell disease
17454192	2007	Retrospective Cohort	Hematology	Pure red cell aplasia incidence, risk factors, and management after major ABO-incompatible allo-HSCT; provides relevant post-HSCT safety context
17180133	2007	Case Report	J Perinatol	Neonatal anaemia and hydrops fetalis following maternal MMF use during pregnancy; important teratogenicity safety signal
15126382	2004	Review	Genetics	Historical perspective on genetics of hemoglobinopathies and lessons from genetics-medicine interface

Philippines Market Information

Mycophenolic acid (including its prodrug mycophenolate mofetil, CellCept® / Myfortic®) currently has no registered products in the Philippines FDA database, with zero license authorizations on record.

For clinical use in Philippine transplant centres, procurement would require an Import License (pursuant to RA 9711 and its IRR) or a hospital-based compassionate/expanded access application submitted to the Philippines FDA. Prescribers should consult the international package insert (Roche CellCept® or Novartis Myfortic®) for complete prescribing information in the interim.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: MMF/MPA has an established, mechanistically well-supported role as GVHD prophylaxis in allo-HSCT for hemoglobinopathy, backed by multiple completed Phase 2 and Phase 4 trials — including an 823-patient multicenter prospective study in thalassemia major and a completed Phase 2 haploidentical BMT trial in sickle cell disease — plus a dedicated 2025 clinical dosing guideline. The evidence base is sufficient to support proceeding, provided that regulatory and safety safeguards appropriate to an unregistered drug in the Philippines are put in place.

To proceed, the following is needed:

Apply for Philippines FDA import license or compassionate use approval before clinical administration
Obtain complete international prescribing information (CellCept® / Myfortic® package insert) to establish local safety protocols covering contraindications, warnings, and major drug interactions
Establish a therapeutic drug monitoring (TDM) protocol for MPA AUC-guided dosing, with particular attention to paediatric thalassemia patients based on the 2025 population PK model
Confirm drug compatibility with locally available HSCT conditioning agents (tacrolimus, cyclosporine, fludarabine, busulfan) and verify local DDI data
Seek ethics committee approval at the designated Philippine transplant centre before initiating any protocol incorporating MMF as GVHD prophylaxis
Implement a pharmacovigilance reporting framework for adverse events in Philippine patients receiving off-label MMF in the HSCT setting
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.